Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLS NASDAQ:INDV NASDAQ:MLTX NASDAQ:URGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLSApellis Pharmaceuticals$28.17+2.2%$22.36$16.10▼$41.94$3.48B0.732.14 million shs1.92 million shsINDVIndivior$24.60+1.3%$19.25$7.33▼$25.00N/A0.812.35 million shs1.60 million shsMLTXMoonLake Immunotherapeutics$58.56+5.0%$52.16$31.42▼$58.99$3.58B1.27375,346 shs676,937 shsURGNUrogen Pharma$19.53+0.4%$17.21$3.42▼$21.01$899.84M1.11.02 million shs1.13 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLSApellis Pharmaceuticals0.00%+0.18%+20.13%+46.49%-29.13%INDVIndivior0.00%+1.12%+15.34%+91.48%+94.24%MLTXMoonLake Immunotherapeutics0.00%+2.05%+5.35%+14.83%+19.15%URGNUrogen Pharma0.00%+5.14%+0.26%+289.00%+39.83%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPLSApellis Pharmaceuticals4.2174 of 5 stars3.33.00.04.42.32.50.6INDVIndivior2.6379 of 5 stars1.64.00.00.01.81.73.1MLTXMoonLake Immunotherapeutics2.3586 of 5 stars3.42.00.00.03.02.50.0URGNUrogen Pharma4.5928 of 5 stars4.53.00.04.52.72.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLSApellis Pharmaceuticals 2.58Moderate Buy$34.1221.11% UpsideINDVIndivior 3.17Buy$22.00-10.57% DownsideMLTXMoonLake Immunotherapeutics 2.78Moderate Buy$74.4327.10% UpsideURGNUrogen Pharma 3.00Buy$32.0063.85% UpsideCurrent Analyst Ratings BreakdownLatest URGN, APLS, MLTX, and INDV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/27/2025INDVIndiviorCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$27.00 ➝ $34.008/18/2025URGNUrogen PharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$36.008/11/2025URGNUrogen PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $40.008/6/2025INDVIndiviorHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$27.008/6/2025MLTXMoonLake ImmunotherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$74.00 ➝ $82.008/5/2025URGNUrogen PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.008/4/2025APLSApellis PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$35.00 ➝ $37.008/1/2025APLSApellis PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$17.00 ➝ $19.008/1/2025APLSApellis PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$39.00 ➝ $40.008/1/2025APLSApellis PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$52.00 ➝ $50.007/29/2025APLSApellis PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$41.00 ➝ $46.00(Data available from 9/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLSApellis Pharmaceuticals$781.37M4.55N/AN/A$1.24 per share22.72INDVIndivior$1.19BN/A$1.84 per share13.34($2.52) per shareN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$5.57 per shareN/AURGNUrogen Pharma$90.40M9.99N/AN/A($2.02) per share-9.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLSApellis Pharmaceuticals-$197.88M-$1.82N/AN/AN/A-30.24%-116.09%-26.72%11/4/2025 (Estimated)INDVIndivior$2M$0.6239.6814.39N/A6.65%-86.28%16.26%10/23/2025 (Estimated)MLTXMoonLake Immunotherapeutics-$118.94M-$2.78N/AN/AN/AN/A-40.98%-35.81%11/6/2025 (Estimated)URGNUrogen Pharma-$126.87M-$3.32N/AN/AN/A-164.44%-97,487.15%-59.38%11/5/2025 (Estimated)Latest URGN, APLS, MLTX, and INDV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025URGNUrogen Pharma-$0.82-$1.05-$0.23-$1.05$23.06 million$24.22 million8/5/2025Q2 2025MLTXMoonLake Immunotherapeutics-$0.73-$0.87-$0.14-$0.87N/AN/A7/31/2025Q2 2025APLSApellis Pharmaceuticals-$0.44-$0.33+$0.11-$0.33$187.91 million$171.39 million7/31/2025Q2 2025INDVIndivior$0.26$0.51+$0.25$0.14$239.43 million$302.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLSApellis PharmaceuticalsN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/AURGNUrogen PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLSApellis Pharmaceuticals2.903.773.16INDVIndiviorN/A0.900.76MLTXMoonLake Immunotherapeutics0.2116.6516.65URGNUrogen PharmaN/A4.143.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLSApellis Pharmaceuticals96.29%INDVIndivior60.33%MLTXMoonLake Immunotherapeutics93.85%URGNUrogen Pharma91.29%Insider OwnershipCompanyInsider OwnershipAPLSApellis Pharmaceuticals6.80%INDVIndiviorN/AMLTXMoonLake Immunotherapeutics12.05%URGNUrogen Pharma4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLSApellis Pharmaceuticals770126.29 million117.70 millionOptionableINDVIndivior1,051N/AN/ANot OptionableMLTXMoonLake Immunotherapeutics264.23 million56.49 millionOptionableURGNUrogen Pharma20046.26 million44.09 millionOptionableURGN, APLS, MLTX, and INDV HeadlinesRecent News About These CompaniesPartners Capital Investment Group LLP Invests $170,000 in Urogen Pharma $URGNAugust 24, 2025 | marketbeat.comUroGen Pharma to Present at Upcoming Investor ConferencesAugust 21, 2025 | globenewswire.comFox Run Management L.L.C. Takes Position in Urogen Pharma $URGNAugust 21, 2025 | marketbeat.comPiper Sandler Initiates Coverage of UroGen Pharma (URGN) with Overweight RecommendationAugust 20, 2025 | msn.comPiper starts ‘underestimated’ UroGen Pharma with an OverweightAugust 19, 2025 | msn.comUroGen Pharma initiated with an Overweight at Piper SandlerAugust 18, 2025 | msn.comUroGen Pharma: Targeting Profits In 2027August 18, 2025 | seekingalpha.comOak Ridge Investments LLC Has $815,000 Position in Urogen Pharma (NASDAQ:URGN)August 17, 2025 | marketbeat.comQ3 EPS Estimates for Urogen Pharma Reduced by HC WainwrightAugust 16, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Insider Mark Schoenberg Sells 10,000 SharesAugust 15, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Receives Consensus Recommendation of "Buy" from BrokeragesAugust 14, 2025 | marketbeat.com17,571 Shares in Urogen Pharma (NASDAQ:URGN) Acquired by Persistent Asset Partners LtdAugust 13, 2025 | marketbeat.comUroGen Pharma’s Earnings Call: Achievements and ChallengesAugust 13, 2025 | msn.comUroGen Pharma Ltd. (NASDAQ:URGN) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | msn.comHC Wainwright Issues Pessimistic Forecast for Urogen Pharma (NASDAQ:URGN) Stock PriceAugust 12, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Releases Earnings Results, Misses Expectations By $0.20 EPSAugust 11, 2025 | marketbeat.comUroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Second-Quarter Results And Analysts Are Updating Their EstimatesAugust 10, 2025 | finance.yahoo.comUroGen Pharma Ltd. (URGN) Q2 2025 Earnings Call TranscriptAugust 9, 2025 | seekingalpha.comUroGen Pharma Ltd. 2025 Q2 - Results - Earnings Call PresentationAugust 9, 2025 | seekingalpha.comUrogen Pharma (NASDAQ:URGN) Stock Price Down 14.4% Following Weak EarningsAugust 8, 2025 | marketbeat.comUroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA Approval and Revenue Growth ...August 8, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeURGN, APLS, MLTX, and INDV Company DescriptionsApellis Pharmaceuticals NASDAQ:APLS$28.17 +0.60 (+2.18%) Closing price 04:00 PM EasternExtended Trading$27.37 -0.80 (-2.84%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.Indivior NASDAQ:INDV$24.60 +0.32 (+1.32%) Closing price 04:00 PM EasternExtended Trading$24.62 +0.02 (+0.08%) As of 05:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.MoonLake Immunotherapeutics NASDAQ:MLTX$58.56 +2.81 (+5.04%) Closing price 04:00 PM EasternExtended Trading$58.60 +0.04 (+0.08%) As of 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.Urogen Pharma NASDAQ:URGN$19.53 +0.08 (+0.41%) Closing price 04:00 PM EasternExtended Trading$19.44 -0.09 (-0.44%) As of 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Tests $412 Support as Options Traders Turn Bullish Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Kohl’s Stock Rebound Faces a Showdown With Short Sellers Amazon Faces Rare Downgrade—Is the Rally at Risk? What to Watch for From D-Wave Now That Earnings Are Done Alibaba Rallies on New AI Chip Design, Sending NVIDIA Stock Lower 3 High-Yield Stocks Just Supercharged Their Dividends Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
